Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. (Q40821920)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

main subject

chronic myeloid leukemia

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Francesco Albano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Elisabetta Abruzzese

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Giuseppe Rossi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Francesco Cavazzini

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Simona Soverini

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Nicoletta Testoni

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Michele Cavo

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Giuseppe Saglio

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

GIMEMA Working Party on Chronic Myeloid Leukemia

17 February 2020

26

object named as

GIMEMA CML Working Party

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

F Castagnetti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

G Gugliotta

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

M Breccia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

A Iurlo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

B Martino

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

L Levato

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

T Intermesoli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

P Pregno

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

F Gherlinzoni

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

P Leoni

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

C Venturi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

G Alimena

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

G Martinelli

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

F Pane

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

G Rosti

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

M Baccarani

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

1 reference

19 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

1823-1831

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2015.152

17 February 2020

exact match

0 references

cites work

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Which TKI? An embarrassment of riches for chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

The impact of health care settings on survival time of patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.152

Chronic Myelogenous Leukemia, Version 1.2014

21 January 2018

1 reference

12 December 2020

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

1 reference

12 December 2020

Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

1 reference

12 December 2020

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

12 December 2020

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

1 reference

12 December 2020

Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2015.152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

17 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26088952%20AND%20SRC:MED&resulttype=core&format=json